Infliximab
Showing 1 - 25 of 774
IBD, Crohn Disease, Ulcerative Colitis Trial (Infliximab)
Not yet recruiting
- Inflammatory Bowel Diseases
- +2 more
- Infliximab
- (no location specified)
Oct 27, 2023
Crohn's Disease Trial in Seoul (Infliximab-Dyyb)
Not yet recruiting
- Crohn's Disease
-
Seoul, Korea, Republic ofAsan Medical Center
Oct 5, 2023
Crohn Disease, Infliximab, Perianal Fistula Due to Crohn's Disease Trial (TDM-based infliximab intravenous therapy, Standard
Not yet recruiting
- Crohn Disease
- +4 more
- TDM-based infliximab intravenous therapy
- Standard infliximab intravenous therapy
- (no location specified)
Sep 26, 2023
Therapeutic Monitoring of Infliximab and Adalimumab
Recruiting
- Inflammatory Bowel Diseases
- Infliximab
- Adalimumab
-
Trieste, ItalyIRCCS Burlo Garofolo
Sep 5, 2023
Crohn Disease Trial in Beijing (Infliximab)
Not yet recruiting
- Crohn Disease
- Infliximab
-
Beijing, ChinaBeijing Children's Hospital, Capital Medical University
Jun 13, 2023
Crohn Disease, Infliximab Trial (Azathioprine, Infliximab)
Not yet recruiting
- Crohn Disease
- Infliximab
- Azathioprine
- Infliximab
- (no location specified)
Apr 3, 2023
Depressive Disorder, Major, Inflammation Trial (Infliximab, Placebo)
Not yet recruiting
- Depressive Disorder, Major
- Inflammation
- Infliximab
- Placebo
- (no location specified)
Nov 21, 2023
90K/Mac-2 BP asIndicator of Early Response to Infliximab Therapy
Not yet recruiting
- IBD
- 90K
- (no location specified)
Jul 18, 2023
Colitis Trial in Aalborg, Odense, London (Infliximab, Methylprednisolone, Prednisolone)
Not yet recruiting
- Colitis
- Infliximab
- +2 more
-
Aalborg, Denmark
- +2 more
Jul 7, 2023
Inflammatory Disease, Disease Crohn, Bowel Disease Trial in Amsterdam (Infliximab subcutaneous, Immunosuppressive Agents)
Recruiting
- Inflammatory Disease
- +2 more
- Infliximab subcutaneous
- Immunosuppressive Agents
-
Amsterdam, North Holland, NetherlandsAmsterdam UMC AMC
Sep 27, 2023
IBD Trial in Paris (Biocollection)
Not yet recruiting
- Inflammatory Bowel Diseases
- Biocollection
-
Paris, FranceSaint Antoine Hospital Service de Gastroentérologie et Nutrition
Feb 1, 2023
EFFICACY AND SAFETY OF S.C. INFLIXIMAB IN PATIENTS SWITCHED FROM
Recruiting
- Inflammatory Bowel Diseases
- Rheumatologic Disease
-
Milano, ItalyIrccs Ospedale San Raffaele
Jan 30, 2023
Medicine Called Infliximab[Infliximab Biosimilar 3] in People
Not yet recruiting
- Arthritis, Rheumatoid
- +3 more
- (no location specified)
Mar 31, 2023
Hidradenitis Suppurativa Trial in Lahore (Infliximab biosimilar)
Active, not recruiting
- Hidradenitis Suppurativa
- Infliximab biosimilar
-
Lahore, Punjab, PakistanServices Institute of Medical Sciences
Dec 22, 2022
Sterile Corneal Melt Trial in Montreal (Topical Infliximab)
Recruiting
- Sterile Corneal Melt
- Topical Infliximab
-
Montreal, Quebec, CanadaCentre Hospitalier de l'Université de Montréal
Dec 12, 2022
Sarcoidosis Trial (STOP arm)
Not yet recruiting
- Sarcoidosis
- STOP arm
- (no location specified)
Jan 16, 2023
Therapeutic Drug Monitoring and Serum TNFa Levels in Pediatric
Completed
- Acute Graft-versus-host Disease
-
Trieste, ItalyIRCCS Burlo Garofolo
Apr 11, 2023
Crohn Disease, Child, Only, Biologic; Inadequate Trial (Infliximab)
Not yet recruiting
- Crohn Disease
- +2 more
- Infliximab
- (no location specified)
Sep 20, 2022
Infliximab in the Treatment of Chinese Crohn's Disease
Active, not recruiting
- Crohn Disease
- Infliximab
-
Guangzhou, China
- +4 more
Jan 31, 2023
Crohn's Disease, Exclusive Enteral Nutrition, Infliximab Trial (Infliximab, Exclusive Enteral Nutrition)
Withdrawn
- Crohn's Disease
- +3 more
- Infliximab
- Exclusive Enteral Nutrition
- (no location specified)
Aug 5, 2022
Medication Belief on Adherence to Infliximab in Crohn's Disease
Completed
- Inflammatory Bowel Diseases
-
Zhejiang, China2ndAffiliated Hospital, School of Medicine, Zhejiang University,
Mar 8, 2023
A 24-month Real Life PErsistence Efficacy and Safety Study in
Recruiting
- Inflammatory Bowel Diseases
- Subcutaneous infliximab CT-P13 Remsima®SC
-
Grenoble, FranceNicolas Mathieu
Aug 2, 2022
IBD Trial in Saint Louis (Infliximab)
Active, not recruiting
- Inflammatory Bowel Diseases
- Infliximab
-
Saint Louis, MissouriWashington University School of Medicine
Aug 31, 2022
Idiopathic Refractory Scleritis Trial (Infliximab, Cyclophosphamide)
Withdrawn
- Idiopathic Refractory Scleritis
- Infliximab
- Cyclophosphamide
- (no location specified)
Jul 18, 2022